Abstract P4-09-14: PhosphohistoneH3 as a prognostic marker in breast cancer: High expression is associated with younger age, triple negative subtype, and disease specific survival

2016 ◽  
Author(s):  
J Craig ◽  
AJ Kovatich ◽  
JA Hooke ◽  
L Kvecher ◽  
J Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Triple Negative ◽  
High Expression ◽  
Disease Specific Survival ◽  
Younger Age ◽  
Disease Specific ◽  
Triple Negative Subtype

scholarly journals High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Huikun Zhang ◽  
Yawen Zhao ◽  
Xiaoli Liu ◽  
Li Fu ◽  
Feng Gu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
High Expression ◽  
Breast Cancer Patients ◽  
The Relationship ◽  
Triple Negative Subtype

BackgroundBreast cancer is the most commonly diagnosed cancer worldwide. However, the well-known biomarkers are not enough to meet the needs of precision medicine. Novel targets are desirable and highly valuable for improved patient survival. In this regard, we identified complement component C7 as one of the candidates based on data from the OCOMINE database.MethodsC7 expression was examined by immunohistochemistry in 331 cases of invasive ductal carcinoma (IDC), 45 cases of ductal carcinoma in situ (DCIS), and 52 cases of non-neoplastic tissues adjacent to tumor. Then, C7 expression was further confirmed by Western blot analysis based on IDC specimens and non-neoplastic breast specimens. The relationship between the C7 expression and prognosis of breast cancer patients was analyzed in order to investigate the function of C7 in breast cancer patients. Meanwhile, we also analyzed the relationship between the C7 expression and prognosis of 149 patients treated with conventional TE (taxane and anthracycline)-based chemotherapy. Then, a cohort of patients (22 cases) treated with TE neoadjuvant chemotherapy was used to further confirm the relationship between the C7 expression and TE-based chemosensitivity.ResultsIn our present study, we reported for the first time that C7 was an independent prognostic factor of breast cancer and C7 expression of IDC tissues was higher than non-neoplastic tissues adjacent to tumor and DCIS. In a cohort of 331 IDC patients, high expression of C7 indicated poor prognosis especially in the triple negative subtype and luminal B subtype. Furthermore, C7 was also a promoting factor for triple negative subtype patients to develop bone metastasis. Meanwhile, we provided the first evidence that patients with high C7 expression were insensitive to TE (taxane and anthracycline)-based chemotherapy by analyzing a cohort of 149 patients treated with TE-based chemotherapy and another cohort of 22 patients treated with TE neoadjuvant chemotherapy.ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.

scholarly journals Kinetic volume analysis on dynamic contrast-enhanced MRI of triple-negative breast cancer: associations with survival outcomes

2020 ◽  
Vol 93 (1106) ◽  
pp. 20190712
Author(s):  
Yoko Hayashi ◽  
Hiroko Satake ◽  
Satoko Ishigaki ◽  
Rintaro Ito ◽  
Mariko Kawamura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Confidence Interval ◽  
Triple Negative ◽  
Hazard Ratio ◽  
Survival Outcomes ◽  
P Value ◽  
Disease Specific Survival ◽  
Contrast Enhanced ◽  
Disease Specific ◽  
Contrast Enhanced Mri

Objective: To evaluate the associations between computer-aided diagnosis (CAD)-generated kinetic volume parameters and survival in triple-negative breast cancer (TNBC) patients. Methods: 40 patients with TNBC who underwent pre-operative MRI between March 2008 and March 2014 were included. We analyzed CAD-generated parameters on dynamic contrast-enhanced MRI, visual MRI assessment, and histopathological data. Cox proportional hazards models were used to determine associations with survival outcomes. Results: 12 of the 40 (30.0%) patients experienced recurrence and 7 died of breast cancer after a median follow-up of 73.6 months. In multivariate analysis, higher percentage volume (%V) with more than 200% initial enhancement rate correlated with worse disease-specific survival (hazard ratio, 1.12; 95% confidence interval, 1.02–1.22; p-value, 0.014) and higher %V with more than 100% initial enhancement rate followed by persistent curve type at 30% threshold correlated with worse disease-specific survival (hazard ratio, 1.33; 95% confidence interval, 1.10–1.61; p-value, 0.004) and disease-free survival (hazard ratio, 1.27; 95% confidence interval, 1.12–1.43; p-value, 0.000). Conclusion: CAD-generated kinetic volume parameters may correlate with survival in TNBC patients. Further study would be necessary to validate our results on larger cohorts. Advances in knowledge: CAD generated kinetic volume parameters on breast MRI can predict recurrence and survival outcome of patients in TNBC. Varying the enhancement threshold improved the predictive performance of CAD generated kinetic volume parameter.

Triple-negative breast cancer survival in women age 75 and older.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1060-1060
Author(s):  
Judith April Malmgren ◽  
Henry G. Kaplan ◽  
Mary K. Atwood
Keyword(s):  
Breast Cancer ◽  
Older Women ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Rank Test ◽  
Disease Specific Survival ◽  
Younger Women ◽  
Log Rank Test ◽  
Disease Specific

1060 Background: Triple-negative breast cancer (TNBC) is associated with a high recurrence rate and poor prognosis, despite high initial response to chemotherapy. It is not known if TNBC patients 75 years older, an age group less likely to be treated with adjuvant chemotherapy, have the same mortality risk as younger women. Methods: We conducted a prospective cohort study of all women presenting with primary TNBC, age 21-89, stage I-III from 1998-2009 identified and tracked by our registry (n=529). Clinical characteristics were chart abstracted at diagnosis and follow up. The Kaplan-Meier method and log rank test were used for disease specific survival (DSS) and overall survival (OS) by age. Results: Mean follow up was 6.6 years, range 1.98-13.41 years. Distribution by age was 92% <75 years (n = 485) and 8% 75+ years (n = 44). The two age groups did not differ by histologic or nuclear grade, stage, or radiation therapy receipt (age 75+ by stage: I = 46%, II = 34%, III 21%, age <75: I = 37%, II = 46%, III = 17% [not significant]). Patients 75 and older were less likely to be treated with adjuvant chemotherapy (32% vs. 91%, Pearson chi square test = 119.32, p <.001). 5 year DSS was not significantly different for patients age <75 years compared to patients age 75+ years (85% vs. 84%). However, 5 year OS was significantly worse for 75 year and older patients (65%) compared to <75 year old patients (83%) (log rank test = 13.97, p < .001). Conclusions: In our institutional cohort, triple-negative breast cancer in older women had similar prognostic indicators (stage and histologic grade) compared to younger women and older women had equivalent disease specific survival in spite of substantially less chemotherapy treatment. At 5 years post diagnosis, women 75 years and older were 18% more likely to die of causes other than breast cancer.

Disparities in the receipt of National Comprehensive Cancer Network (NCCN) guideline adherent care in triple-negative breast cancer (TNBC) by race/ethnicity, socioeconomic status, and insurance type.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1080-1080
Author(s):  
Chimezie Ubbaonu ◽  
Jenny Chang ◽  
Argyrios Ziogas ◽  
Kiran Clair ◽  
Sora Park Tanjasiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Socioeconomic Status ◽  
Triple Negative ◽  
Disease Specific Survival ◽  
Nccn Guidelines ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Cancer Network ◽  
To Receive ◽  
Disease Specific

1080 Background: Breast cancer is the most commonly diagnosed cancer in women in the United States and the second leading cause of cancer mortality in women.TNBC is more likely to present at an earlier age with more advanced and aggressive disease. The overarching goal of treatment recommendations listed in the National Comprehensive Cancer Network (NCCN) guidelines are to improve patient outcomes. Here we examine factors which may contribute to NCCN guideline adherence. Methods: This was a retrospective cohort study of women with triple negative breast cancer using data from the California Cancer Registry (CCR) between 2004-2016 (with follow-up through 11/2018). Indicators for concordance with NCCN guidelines for TNBC was used as the dependent variable in the analysis. A multivariable logistic regression was used to determine the effects of independent variables on adherence to NCCN guidelines. Odds ratios and 95% Confidence Intervals (CI) were calculated. Non-Hispanic Whites, having medical insurance and highest socioeconomic status (SES) were set as references values in the regression models. Disease specific survival was calculated using the Cox regression analysis. Results: A total of 16,858 women were included in this study, 32.5% (n = 5,472) received NCCN adherent care (p < 0.0001). Non-Hispanic Blacks (NHB) and Hispanic patients were less likely to receive guideline adherent care (respectively, OR 0.87, 95%CI 0.79-0.95 and OR 0.87, 95%CI 0.79-0.95). Patients of lowest and lower-middle socioeconomic status (SES) were less likely to receive NCCN guideline adherent care (respectively, OR 0.77, 95%CI 0.68-0.87 and OR 0.88, 95%CI 0.79-0.98). Overall, non-adherent care was associated with an increased disease-specific mortality (HR 1.21, 95%CI 1.11-1.31, p < 0.0001). Hazard ratios were calculated after adjusting for adherent care and NHB patients had an increased disease-specific mortality (HR 1.28, 95%CI 1.16-1.42, p < 0.0001) in addition to patients with Medicare or Medicaid payer status (respectively, HR 1.20, 95%CI 1.08-1.34, p < 0.001 and HR 1.29, 95%CI 1.15-1.43, p < 0.0001). Conclusions: A significant portion of TNBC patients in California continue to receive non-guideline adherent care. Non-Hispanic black patients and lower SES quintile groups were less likely to receive guideline adherent care. Patients with non-adherent care had worse disease specific survival compared to recipients of NCCN-adherent care.

scholarly journals 113P Impact of local recurrence on disease-specific survival in breast cancer patients who underwent breast-conserving surgery

2020 ◽  
Vol 31 ◽  
pp. S54
Author(s):  
D.G. Tiezzi ◽  
L. de Mattos ◽  
L.F. Orlandini ◽  
F.J. Candido Dos Reis ◽  
H.H. Carrara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Cancer Patients ◽  
Breast Conserving Surgery ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
Disease Specific

scholarly journals Genomic Profile of Early Stage Node-Negative Luminal Breast Cancer Associated with Short Disease-Specific Survival

2014 ◽  
Vol 25 ◽  
pp. iv95
Author(s):  
A. Durigova ◽  
P. Tsantoulis ◽  
R. Lyle ◽  
C. Borel ◽  
G. Fioretta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Luminal Breast Cancer ◽  
Genomic Profile ◽  
Disease Specific Survival ◽  
Node Negative ◽  
Disease Specific

BTN3A2 serves as a prognostic marker and favors immune infiltration in triple‐negative breast cancer

2019 ◽  
Vol 121 (3) ◽  
pp. 2643-2654 ◽  
Author(s):  
Peian Cai ◽  
Zhenhui Lu ◽  
Jianjun Wu ◽  
Xiong Qin ◽  
Zetao Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Immune Infiltration

Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin

2000 ◽  
Vol 18 (3) ◽  
pp. 574-574 ◽  
Author(s):  
S. von Mensdorff-Pouilly ◽  
A.A. Verstraeten ◽  
P. Kenemans ◽  
F.G. M. Snijdewint ◽  
A. Kok ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Humoral Response ◽  
Disease Specific Survival ◽  
Breast Cancer Patients ◽  
Antibody Levels ◽  
Pretreatment Serum ◽  
Test Result ◽  
Disease Specific

PURPOSE: Polymorphic epithelial mucin (PEM or MUC1) is being studied as a vaccine substrate for the immunotherapy of patients with adenocarcinoma. The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease.MATERIALS AND METHODS: We measured immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to MUC1 with an enzyme-linked immunoassay (PEM.CIg), which uses a MUC1 triple-tandem repeat peptide conjugated to bovine serum albumin, in pretreatment serum samples obtained from 154 breast cancer patients (52 with stage I disease and 102 with stage II) and 302 controls. The median disease-specific survival time of breast cancer patients was 74 months (range, 15 to 118 months). A positive test result was defined as MUC1 IgG or IgM antibody levels equal to or greater than the corresponding rounded-up median results obtained in the total breast cancer population.RESULTS: A positive test result for both MUC1 IgG and IgM antibodies in pretreatment serum was associated with a significant benefit in disease-specific survival in stage I and II (P = .0116) breast cancer patients. Positive IgG and IgM MUC1 antibody levels had significant additional prognostic value to stage (P = .0437) in multivariate analysis. Disease-free survival probability did not differ significantly. However, stage II patients who tested positive for MUC1 IgG and IgM antibody and who relapsed had predominantly local recurrences or contralateral disease, as opposed to recurrences at distant sites in the patients with a negative humoral response (P = .026).CONCLUSION: Early breast cancer patients with a natural humoral response to MUC1 have a higher probability of freedom from distant failure and a better disease-specific survival. MUC1 antibodies may control hematogenic tumor dissemination and outgrowth by aiding the destruction of circulating or seeded MUC1-expressing tumor cells. Vaccination of breast cancer patients with MUC1-derived (glyco)peptides in an adjuvant setting may favorably influence the outcome of disease.

Sign in / Sign up

Export Citation Format

Share Document